Cardiovascular Drugs Practice Questions

Q: Activation of which of the following receptors causes vasoconstriction?

ETa receptor. **Explanation:** The correct answer is **D. ETa receptor**. **1. Why ETa receptor is correct:** Endothelin-1 (ET-1) is one of the most potent endogenous vasoconstrictors known [2]. It acts primarily through two G-protein coupled receptors: **ETa** and **ETb**. * **ETa receptors** are located on vascular smooth muscle cells [3]. Their activation leads to an increase in intracellular calcium, resulting in profound and prolonged **vasoconstriction** [1]. * (Note: ETb receptors on the endothelium actually cause vasodilation via NO release, but ETa is the dominant mediator of constriction). **2. Why the other options are incorrect:** * **Nm receptor (Option A):** These are nicotinic receptors found at the **Neuromuscular Junction**. Their activation leads to skeletal muscle contraction, not vascular smooth muscle action. * **M3 receptor (Option B):** While M3 receptors are present on vascular endothelium, their activation triggers the release of Nitric Oxide (EDRF), which leads to **vasodilation**. (In the absence of endothelium, they can cause constriction, but physiologically they are associated with dilation). * **Nn receptor (Option C):** These are nicotinic receptors found in **Autonomic Ganglia** and the adrenal medulla. While they mediate neurotransmission, they do not directly cause vasoconstriction; any vascular effect would be indirect via sympathetic ganglionic stimulation. **3. Clinical Pearls for NEET-PG:** * **Bosentan:** A dual ETa and ETb receptor antagonist used in the treatment of **Pulmonary Arterial Hypertension (PAH)** [4]. * **Ambrisentan:** A selective ETa receptor antagonist also used for PAH. * **High-Yield Constrictors:** Remember the "Big Three" for exams: **Alpha-1 (α1)**, **Angiotensin II (AT1)**, and **Endothelin (ETa)**. * **M3 Paradox:** M3 activation causes *contraction* of all smooth muscles (gut, bladder, bronchi) **EXCEPT** vascular smooth muscle, where it causes *relaxation* (via NO).

Q: What is the drug available for the treatment of resistant cases of atrial fibrillation?

Amiodarone. **Explanation:** **Amiodarone** is the drug of choice for resistant or refractory atrial fibrillation (AF) due to its unique pharmacological profile. It is a Class III antiarrhythmic that primarily blocks potassium channels, prolonging the action potential duration and effective refractory period. However, it also possesses Class I (sodium channel), Class II (beta-blocking), and Class IV (calcium channel) activities. This "broad-spectrum" effect makes it highly effective in maintaining sinus rhythm when other agents fail, especially in patients with structural heart disease or heart failure. **Why other options are incorrect:** * **Quinidine (Class IA):** While it can convert AF to sinus rhythm, it is rarely used today due to significant side effects (cinchonism, thrombocytopenia) and the risk of "Quinidine syncope" caused by Torsades de Pointes. * **Propranolol (Class II):** Beta-blockers are excellent for **rate control** in AF, but they are generally not effective for converting resistant AF back to sinus rhythm (rhythm control). * **Digoxin:** It is used for rate control in AF, particularly in sedentary patients or those with heart failure. However, it is ineffective for rhythm conversion and does not work well during high-sympathetic states (like exercise). **Clinical Pearls for NEET-PG:** * **Drug of Choice:** Amiodarone is the preferred drug for AF in patients with **congestive heart failure (CHF)** or myocardial infarction. * **Side Effects:** High-yield for exams! Watch for pulmonary fibrosis, thyroid dysfunction (due to high iodine content), corneal microdeposits, and "blue-gray" skin discoloration. * **Monitoring:** Patients on long-term Amiodarone require periodic Liver Function Tests (LFTs), Thyroid Function Tests (TFTs), and Chest X-rays.

Q: Which of the following statements regarding carvedilol is incorrect?

Its oral bioavailability is approximately 80%.. ### Explanation **Why Option B is the correct answer (Incorrect Statement):** Carvedilol undergoes **extensive first-pass metabolism** in the liver. Consequently, its oral bioavailability is quite low, approximately **25% to 30%**, not 80%. This is a high-yield pharmacokinetic property often tested in competitive exams to differentiate it from other beta-blockers. **Analysis of Other Options:** * **Option A:** Carvedilol is a **non-selective beta-blocker** (blocks $\beta_1$ and $\beta_2$) that also possesses **$\alpha_1$-blocking** activity. The ratio of $\alpha$ to $\beta$ blockade is approximately 1:10. This dual action leads to peripheral vasodilation along with reduced heart rate. * **Option C:** It is unique among beta-blockers for its **antioxidant and anti-proliferative properties**. It scavenges free radicals and inhibits lipid peroxidation, which helps prevent vascular smooth muscle hypertrophy and remodeling. * **Option D:** Carvedilol is a cornerstone in the management of **Congestive Heart Failure (CHF)**. By reducing afterload (via $\alpha_1$ blockade) and protecting the myocardium from catecholamine-induced toxicity, it significantly reduces mortality and hospitalization in CHF patients (as proven in the COPERNICUS and CAPRICORN trials). **Clinical Pearls for NEET-PG:** * **Lipophilicity:** Carvedilol is highly lipophilic. * **Metabolism:** It is primarily metabolized by CYP2D6 and CYP2C9; genetic polymorphisms in these enzymes can affect drug levels. * **The "Big Three" in CHF:** Carvedilol, Metoprolol succinate, and Bisoprolol are the three beta-blockers specifically proven to reduce mortality in chronic heart failure. * **Contraindication:** Like other non-selective beta-blockers, it should be avoided in patients with bronchial asthma due to $\beta_2$ blockade.

Q: Hyperlipidemia can be caused by the intake of which of the following drug classes?

Beta-blockers. **Explanation:** **Why Beta-blockers are the correct answer:** Non-selective beta-blockers (like Propranolol) and even some selective $\beta_1$ blockers can adversely affect the lipid profile. The primary mechanism involves the inhibition of **Lipoprotein Lipase (LPL)**, the enzyme responsible for clearing triglycerides from the blood. Additionally, blocking $\beta_2$ receptors on adipocytes reduces the activity of hormone-sensitive lipase, leading to: * **Increased Triglycerides (VLDL)** * **Decreased HDL ("Good") cholesterol** * Minimal to no effect on LDL. * *Note:* Beta-blockers with Intrinsic Sympathomimetic Activity (ISA) like Pindolol or vasodilatory beta-blockers like Carvedilol/Nebivolol have a neutral or even beneficial effect on lipids. **Analysis of Incorrect Options:** * **A. Calcium Channel Blockers (CCBs):** These are metabolically neutral. They do not significantly affect glucose or lipid metabolism, making them a preferred choice in hypertensive patients with dyslipidemia or diabetes. * **C. Methyldopa:** A centrally acting $\alpha_2$ agonist used primarily in pregnancy-induced hypertension; it does not cause hyperlipidemia. * **D. Reserpine:** An older adrenergic neuron blocker that depletes catecholamines; it is not associated with lipid abnormalities. **NEET-PG High-Yield Pearls:** 1. **Thiazide Diuretics** also cause hyperlipidemia (increased LDL and TG) and hyperglycemia. 2. **Alpha-blockers** (e.g., Prazosin) are "lipid-friendly" as they increase HDL and decrease LDL/TG. 3. **Drug of choice** for hypertension with co-existing dyslipidemia: ACE inhibitors, ARBs, or CCBs. 4. **Metabolic Syndrome:** Avoid combining Thiazides and Beta-blockers as both worsen insulin sensitivity and lipid profiles.

Q: What centrally acting sympatholytic agent is used as an antihypertensive agent?

Clonidine. **Clonidine** is the correct answer because it is a potent **central alpha-2 ($\alpha_2$) adrenergic agonist** [1, 2]. It acts on the $\alpha_2$ receptors in the vasomotor center of the medulla (solitary tract nucleus) [1]. Stimulation of these receptors leads to a decrease in sympathetic outflow from the CNS to the heart and peripheral vasculature, resulting in a reduction in blood pressure and heart rate [1, 2, 3]. **Analysis of Incorrect Options:** * **Propranolol (Option A):** This is a non-selective **beta-blocker**. While it reduces blood pressure, its primary mechanism is peripheral (decreasing cardiac output and renin release), not central sympatholysis. * **Prazosin (Option C):** This is a selective **alpha-1 ($\alpha_1$) blocker**. It acts peripherally on vascular smooth muscle to cause vasodilation; it does not have a central sympatholytic mechanism. * **Phenoxybenzamine (Option D):** This is a non-selective, irreversible **alpha-blocker** used primarily in the preoperative management of pheochromocytoma. It acts peripherally. **High-Yield NEET-PG Pearls:** * **Rebound Hypertension:** Sudden withdrawal of Clonidine can cause a hypertensive crisis due to a massive surge in catecholamines. It should always be tapered. * **Other Centrally Acting Agents:** **Methyldopa** is another key example; it is the drug of choice for hypertension in pregnancy [1, 3]. * **Side Effects:** Common side effects of Clonidine include sedation, dry mouth (xerostomia), and depression [2, 3]. * **Diagnostic Use:** The "Clonidine Suppression Test" is used to diagnose pheochromocytoma (plasma catecholamines fail to drop in affected patients) [2].

Q: Characteristic adverse effect of quinidine includes:

Cinchonism. **Explanation:** **Quinidine** is a Class IA antiarrhythmic drug derived from the cinchona bark. The correct answer is **Cinchonism**, which is the hallmark toxicity associated with quinidine overdose or chronic use. 1. **Why Cinchonism is correct:** Quinidine is an optical isomer of quinine. Cinchonism is a toxicological syndrome characterized by neurological and auditory symptoms, including **tinnitus (ear ringing)**, blurred vision, hearing loss, headache, dizziness, and confusion. In severe cases, it can lead to gastrointestinal distress and photophobia. 2. **Why other options are incorrect:** * **Lupus Erythematosus:** This is a classic side effect of **Procainamide** (another Class IA drug) and Hydralazine, but not typically associated with Quinidine. * **Increase in Digoxin Clearance:** This is factually incorrect. Quinidine actually **decreases** the renal and biliary clearance of digoxin by displacing it from tissue binding sites and inhibiting P-glycoprotein. This leads to a dangerous **increase in plasma digoxin levels**, doubling the risk of digitalis toxicity. * **Precipitation of Hyperthyroidism:** This is a characteristic side effect of **Amiodarone** (Class III), which contains iodine in its structure, not Quinidine. **High-Yield Clinical Pearls for NEET-PG:** * **ECG Changes:** Quinidine causes **QT interval prolongation**, which can predispose patients to **Torsades de Pointes** (polymorphic ventricular tachycardia). * **Vagal Effect:** It has potent antimuscarinic (atropine-like) properties, which can paradoxically increase AV conduction. * **Alpha-blockade:** It can cause peripheral vasodilation leading to hypotension. * **Hematology:** It is a known cause of immune-mediated **thrombocytopenia**.

Q: Which one of the following drugs is not converted to an active metabolite?

Lisinopril. ### Explanation The question tests your knowledge of **ACE Inhibitors (ACEIs)** and their pharmacokinetic profiles, specifically the concept of **prodrugs**. #### 1. Why Lisinopril is the Correct Answer Most ACE inhibitors are **prodrugs**; they are relatively inactive and must undergo hepatic metabolism (esterification) to be converted into their active "–at" forms (e.g., Enalapril to Enalaprilat). **Lisinopril** and **Captopril** are the two primary exceptions to this rule. Lisinopril is already in its active form when ingested and does not require hepatic activation. This makes it particularly useful in patients with hepatic impairment. It is excreted unchanged by the kidneys. #### 2. Why the Other Options are Incorrect * **A. Quinapril:** It is a prodrug converted in the liver to its active metabolite, **Quinaprilat**. * **B. Fosinopril:** It is a prodrug converted to **Fosinoprilat**. It is unique because it has balanced dual excretion (both renal and biliary), making it safer in renal failure. * **C. Benazepril:** It is a prodrug converted to **Benazeprilat**. #### 3. High-Yield Clinical Pearls for NEET-PG * **The "Pril" Rule:** All ACE inhibitors are prodrugs **EXCEPT** Captopril and Lisinopril. * **Active Metabolites:** The active form of an ACE inhibitor usually ends in **"-at"** (e.g., Ramipril $\rightarrow$ Ramiprilat). * **Pharmacokinetics:** Since Lisinopril is not metabolized by the liver, its bioavailability is not affected by hepatic function, but its dose must be adjusted in renal failure. * **Side Effects:** Remember the mnemonic **CAPTOPRIL** (Cough, Angioedema, Proteinuria, Taste changes, Orthostatic hypotension, Pregnancy contraindication, Renal artery stenosis contraindication, Increased potassium, Leukopenia).

Q: A 54-year-old man has a total cholesterol of 272 mg/dL and LDL level of 210 mg/dL. His therapy is initiated with dietary modification and an exercise regimen, but he is unresponsive and is subsequently prescribed nicotinic acid (Niacin). Which of the following symptoms will this patient likely experience from this drug?

Facial flushing. **Explanation:** **1. Why Facial Flushing is Correct:** Niacin (Vitamin B3) is a potent lipid-lowering agent that inhibits lipolysis in adipose tissue. The most common and characteristic side effect of Niacin is **cutaneous flushing and pruritus** (especially of the face and upper body). This occurs because Niacin triggers the release of **Prostaglandin D2 and E2** in the skin, leading to vasodilation. * **Clinical Management:** This effect is mediated by prostaglandins, not histamine; therefore, it can be blunted by pre-treating the patient with **Aspirin** (an NSAID) 30 minutes before the Niacin dose. **2. Why Other Options are Incorrect:** * **A. Bradycardia:** Niacin does not affect the heart rate directly. In fact, the vasodilation-induced flushing can sometimes cause mild reflex tachycardia. * **C. Hypoalbuminemia:** Niacin does not interfere with protein synthesis or renal excretion of albumin. However, it is known to be **hepatotoxic** (elevated LFTs), which is a high-yield monitoring parameter. * **D. Hypoglycemia:** Niacin actually causes **Hyperglycemia** (due to increased insulin resistance). It should be used with caution in diabetic patients. **3. NEET-PG High-Yield Pearls:** * **Mechanism:** Inhibits hormone-sensitive lipase in adipose tissue → decreased FFA flux to liver → decreased VLDL and LDL synthesis. * **Best Effect:** Niacin is the most effective agent for **increasing HDL levels**. * **Side Effect Profile (The "3 Hypers"):** 1. **Hyper**glycemia (caution in Diabetes). 2. **Hyper**uricemia (can precipitate Gout). 3. **Hyper**pigmentation (Acanthosis nigricans). * **Drug of Choice:** It is also used to treat **Pellagra** (Dermatitis, Diarrhea, Dementia).

Q: Which of the following drugs acts as an arteriolar dilator used in the treatment of Congestive Heart Failure (CHF)?

Hydralazine. **Explanation:** **Hydralazine** is a direct-acting **arteriolar vasodilator**. In the context of Congestive Heart Failure (CHF), it reduces **afterload**, which decreases the resistance against which the left ventricle must pump. This improves cardiac output and stroke volume. It is particularly effective when combined with Isosorbide Dinitrate (BiDil), a combination proven to reduce mortality in patients with heart failure, especially in the African American population. **Analysis of Incorrect Options:** * **Nifedipine:** While it is a Calcium Channel Blocker (CCB) that causes vasodilation, it is generally **avoided in CHF** (especially with reduced ejection fraction) due to its negative inotropic effects and potential to cause reflex tachycardia and fluid retention. * **Prazosin:** This is an alpha-1 blocker that acts as a **balanced vasodilator** (dilating both arterioles and veins). While it reduces both preload and afterload, it is not a first-line agent for CHF and is prone to the "first-dose effect" (orthostatic hypotension). * **Enalapril:** This is an ACE inhibitor. Like Prazosin, it is a **balanced vasodilator** (affects both resistance and capacitance vessels) by inhibiting Angiotensin II and increasing Bradykinin. It is a cornerstone of CHF therapy but is not classified as a pure arteriolar dilator. **High-Yield Clinical Pearls for NEET-PG:** * **Drug-Induced Lupus Erythematosus (DILE):** Hydralazine is a classic cause (associated with anti-histone antibodies). * **Nitrate + Hydralazine:** This combination is the preferred alternative for CHF patients who cannot tolerate ACE inhibitors or ARBs due to renal failure or hyperkalemia. * **Reflex Tachycardia:** Because Hydralazine causes significant baroreceptor-mediated sympathetic activation, it is often co-administered with a beta-blocker in hypertensive emergencies.

Q: Losartan is similar to enalapril in all of the following features except:

Potential to induce cough in susceptible individuals. **Explanation:** The core difference between **ACE Inhibitors (ACEIs)** like Enalapril and **Angiotensin Receptor Blockers (ARBs)** like Losartan lies in their mechanism of action regarding the kinin system. **1. Why Option D is correct:** ACE inhibitors (Enalapril) block the enzyme *Angiotensin Converting Enzyme*, which is also responsible for the degradation of **bradykinin** and **Substance P** [1]. Accumulation of these pro-inflammatory peptides in the lungs triggers the dry, irritating cough seen in 5-20% of patients [1]. In contrast, Losartan blocks the $AT_1$ receptor directly and has no effect on ACE; therefore, it does not lead to bradykinin accumulation and **does not induce cough** [2]. **2. Why the other options are incorrect:** * **Option A (Anti-hypertensive efficacy):** Both ACEIs and ARBs are equally effective first-line agents for managing hypertension [2]. * **Option B (Reversal of LVH):** Both drug classes effectively inhibit the trophic effects of Angiotensin II on the myocardium, promoting the regression of left ventricular hypertrophy (LVH) [2]. * **Option C (Carbohydrate tolerance):** Both classes are "metabolically neutral." Unlike beta-blockers or thiazides, they do not impair glucose tolerance and are, in fact, the preferred drugs for hypertensive patients with Diabetes Mellitus due to their nephroprotective effects [1]. **High-Yield NEET-PG Pearls:** * **Drug of Choice:** ARBs (Losartan) are the preferred alternative for patients who develop a cough while on ACE inhibitors [1]. * **Teratogenicity:** Both ACEIs and ARBs are **strictly contraindicated in pregnancy** (Category X) as they cause fetal renal anomalies and oligohydramnios. * **Side Effects:** Both can cause hyperkalemia and angioedema (though angioedema is much rarer with ARBs) [1]. * **Losartan Unique Property:** It has a mild **uricosuric effect**, making it beneficial for hypertensive patients with gout.

Question 1

Activation of which of the following receptors causes vasoconstriction?

Accepted Answer

ETa receptor

Answer

Nm receptor

Answer

M3 receptor

Answer

Nn receptor

Question 2

What is the drug available for the treatment of resistant cases of atrial fibrillation?

Accepted Answer

Amiodarone

Answer

Quinidine

Answer

Propranolol

Answer

Digoxin

Question 3

Which of the following statements regarding carvedilol is incorrect?

Accepted Answer

Its oral bioavailability is approximately 80%.

Answer

It is a beta-1, beta-2, and alpha-1 adrenergic receptor blocker.

Answer

It possesses antioxidant properties.

Answer

It is cardioprotective in patients with congestive heart failure.

Question 4

Hyperlipidemia can be caused by the intake of which of the following drug classes?

Accepted Answer

Beta-blockers

Answer

Calcium channel blockers

Answer

Methyldopa

Answer

Reserpine

Question 5

What centrally acting sympatholytic agent is used as an antihypertensive agent?

Accepted Answer

Clonidine

Answer

Propranolol

Answer

Prazosin

Answer

Phenoxybenzamine

Question 6

Characteristic adverse effect of quinidine includes:

Accepted Answer

Cinchonism

Answer

Lupus erythematosis

Answer

Increase in digoxin clearance

Answer

Precipitation of hyperthyroidism

Question 7

Which one of the following drugs is not converted to an active metabolite?

Accepted Answer

Lisinopril

Answer

Quinapril

Answer

Fosinopril

Answer

Benazepril

Question 8

A 54-year-old man has a total cholesterol of 272 mg/dL and LDL level of 210 mg/dL. His therapy is initiated with dietary modification and an exercise regimen, but he is unresponsive and is subsequently prescribed nicotinic acid (Niacin). Which of the following symptoms will this patient likely experience from this drug?

Accepted Answer

Facial flushing

Answer

Bradycardia

Answer

Hypoalbuminemia

Answer

Hypoglycemia

Question 9

Which of the following drugs acts as an arteriolar dilator used in the treatment of Congestive Heart Failure (CHF)?

Accepted Answer

Hydralazine

Answer

Nifedipine

Answer

Prazosin

Answer

Enalapril

Question 10

Losartan is similar to enalapril in all of the following features except:

Accepted Answer

Potential to induce cough in susceptible individuals

Answer

Anti-hypertensive efficacy

Answer

Potential to reverse left ventricular hypertrophy

Answer

Lack of effect on carbohydrate tolerance

Cardiovascular Drugs — MCQs

Cardiovascular Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?